We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The $845-per-month list price AbbVie set for its just-approved endometriosis drug Orilissa is reasonable enough, a U.S. cost-effectiveness watchdog figures. But payers should consider requiring women to try other treatments first.